Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
EVENITY - official renal safety check
Product / population
EVENITY - official renal safety check; selected renal passages, not a complete prescribing monograph.
DailyMed / Amgen Inc. · EVENITY - official renal safety check; selected renal passages, not a complete prescribing monograph.
Renal method: eGFR, mL/min/1.73 m2; preserve body-surface-area indexing. Source date: Prescribing information revised January 2026. Retrieved: 2026-09-09
Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The label retains no renal dose adjustment alongside greater hypocalcemia risk at eGFR 15-29 mL/min/1.73 m2 or during dialysis. Correct low calcium beforehand, monitor serum calcium in these high-risk patients, and provide calcium/vitamin D. No renal adjustment does not establish overall treatment eligibility: do not initiate EVENITY in a patient with myocardial infarction or stroke within the preceding year. No numerical renal dose reduction or fixed calcium-monitoring interval is inferred from these sections.
RDM52-official-romosozumab-evenity-7c3f920f54-C1 · Source locator: Sections 8.7, 5.3 and 5.1; prescribing-information revision and label header.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.